María Ana Martinez-Castellanos

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Lihteh Wu, María Ana Martinez-Castellanos, Hugo Quiroz–Mercado et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2007 · 454 citations

Ocular Disease, Vitreous Body, Experimental Ophthalmology +4

ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY

Hugo Quiroz-Mercado, María Ana Martinez-Castellanos, Myriam Lucía Hernández-Rojas et al. · Retina · 2008 · 142 citations

LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

María Ana Martinez-Castellanos, Shulamit Schwartz, Myriam Lucía Hernández-Rojas et al. · Retina · 2012 · 116 citations

Expert Diagnosis of Plus Disease in Retinopathy of Prematurity From Computer-Based Image Analysis

J. Peter Campbell, Esra Ataer-Cansızoğlu, Verónica Bolón‐Canedo et al. · JAMA Ophthalmology · 2016 · 116 citations · Full text

Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity

María Ana Martinez-Castellanos, Shulamit Schwartz, Gerardo García‐Aguirre et al. · British Journal of Ophthalmology · 2012 · 99 citations